References

1. Alcaide, F Carratala, J, Ares, J, Guidiol, F& Martin R (1996). *In vitro* activities of eight macrolide antibiotics and RP-59.500 (quinupristin-dalfopristin) against viridans group streptococci Isolates from blood of neutropenic cancer patient. Antimicrobial Agents and chemotherapy 40, 2117-20.
2. Andrews, T.M.A weller-, J-P Ashby, R.M. Walker and R. wise (2000). The *in vitro* activity of ABT 773, anew Ketohide anti Mirobial agent. Journal of antimicrobial chemotherapy department of medical microbiology UK; 46/6/ P 1017-1022.
3. Betty A Forbes, Daniel F. Sahm Alices. Weissfeld,(1998). Chapter 53: Streptococcus, Enterococcus, and similar organisms. Bailey & Scott's Diagnostic Microbiology. 10th ed P 259,.620-632.
4. Bizjak, ED and Mauro VF (1997). Digoxin-Macrolide drug interaction. Ann Pharmacother; 31: 1077-9.
5. Cheesbrough (2000). Antimicrobial Sensitivity testing District Laboratory practice In Tropical countries part 2 Cambridge. U.K. Low Price Edition P.132-143.
6. Collins, Partricia M hyne JM Grange (1995) Antimicrobial susceptibility tests. Microbiological methods. Butterworth-Heinemann LTD printed in Great Britain, 7th ed, P 178-189.
7. Combel, JF Corota, Neut, Romond c, (1987). Yoghurt with Bifidobacterium Longum reduces erythromycin Induced gastro intestinal effects, Lancet; ii: 43

8. Conhy, J and Stein K (1994). Reduction of Vitamin K_2 in human Liver associated with use of broad-spectrum antimicrobials. Clin invest Med; 17:531-9.
9. DAIS, Dul BECCO. EISEN. GINSBERG wood (1972). 23 Streptococci, Microbiology Acknowledgments P 702-724. Edition 7 printed with corrections 1972 HOEBR Medical Division London.
10. Deverll; Yassin HM (2001). Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections. Expert opinion Investigations Drugs; 10: 353-367.
11. Dubos (1958). The Haemolytic streptococci, Bacterial and Mycotic Infections of Man. 3rded, London. Pitman Medical Publishing Co., Ltd. P 248.
12. Ednie, LM; Visalli, MA; Jaccobs, MR; Appelbaum, PC, (1996). Comparative activities of clarithromycin, erythromycin, and azithromycin against Penicillin- susceptible and Penicillin-resistant Pneumococci. Department of pathology (clinical microbiology), Hershey medical centere, Pennsylvania 17033, U.S.A. Antimicrob – Agents- Chemother- Aug; 40 (8): 1950-2.
13. Emer, GW, Surawiczcm, McFarland LV (1996). Biotherapeutic agents. Aneglected modality for the treatment and prevention of selected Intestinal and vaginal infections. JAMA; 275: 870-6.
14. Holt, GA (1998). Food and drug interactions. Chicago: Precept press, 107-8.
15. Iciar R. Guez-Avial, Carmen R. Esther Culebras, Antonio B and Tuanj, P. (2001). Distribution of mef (A) and erm (B) genes in macrolide-resistant blood isolates of Viridans group streptococci. Journal of antimicrobial chemotherapy 47, 727-728.

16. James CMAC (1998) Erythromycin and other Macrolides, LEwis's Pharmacology FiBiol Nottinham Fifth edition P 842-843.
17. Joklik, Willett, Amos, Wilfert, (1988). Chapter 26 streptococcus. Zinsser Microbiology.19th ed, Lange Clifornia USA P. 357-366, 368-376
18. Jorgensen, JH; Swenson, JM; Tenovor, FC; Barry, A; Ferraro, MJ; Murray, PR; Reller, LB, (1996). Development of interpretive criteria and quality control limits for Macrolides and Clindomycin susceptibility testing of *Streptococcus pneumoniae*. J. Clin. Microbial No V; 34 (II): P 2679-84, U.S.A.
19. Kanail, Muklterice (1994). Antimicrobial susceptibility test, Medical Laboratory Technology. A procedure Manual for Routine Diagnostic tests Volume II. Ninth Reprint Published by TATA McGraw Hill publishing Company Limited New Delhi P. 616.
20. Kaplan, EL, (1991). The resurgence of group A Streptococcal infections and their sequelae. Eurjclin Microbiol infect Dis; 10:55-7.
21. Mackie & McCartney (1996). Laboratory Control of antimicrobial therapy, Specimen Collection, culture containers and media culture of bacteria. Practical Medical Microbiology Fourteenth Edition P 95-122,113-130, 151- 177 Churchill Livingstone, produced by Long man Singapore Publishers (Pte) LTD.
22. Maruyama, SH Yoshioka H, Fujitak, Takimoto M, Satake Y (1979). Sensitivity of group A Streptococci to antibiotics: prevalence of resistance to erythromycin in Japan. AM J Dis Child; 133:1143-5
23. Neubauer, RA (1961). A plant protease for potentiation, Exp Med Surg; 19:143-60.

24. Nishioka, K; Ogihara, H; Ohonol; Tanno, Y; Shirato, K (1996). The incidence of respiratory tract pathogens and antimicrobial susceptibilities of *Streptococcus pneumoniae*, Haemophilis isolated between 1990-1993. Tohoku-j-EXP-Med. jun; 179 (2): 111-21.

25. Paula, A, (1991). Chapter 35 Macrollides, Tetraclines and Sulfonamides. Harrison's principles of internal medicine. 12th Edition. P 439-492.

26. Phillips, G Parratt D, orange GV, Harper 1, Mc Ewan H, Young N (1990). Erythromycin- resistant *Streptococcus pyogenes*. J Antimicrob Chemother; 25: 723-4.

27. Prado, V; Romero-j; Herrera-N; Marinkovic-K; Bustos-R (1993), Comprative Invitro activity of new oral Macrolides against *Stryptococcus pyogenes* strains. ReV-Med-chil- Oct; 121 (10): 1128-38.

28. Rang, (1999). Chapter 43, Pharmacology 4th ed, Churchill Livingstone, London P.696.

29. Rubin, (2002) wake Forest University School of medicine. O Macrolide Effects November 2002.

30. Schellenberg, D. Bonington A, Champion CM, *et al*. (1994). Treatment of Clostridium difficle diarrhoea with brewer's yeast Lancet; 343: 171-2

31. Seppala, H Nissinen A, Jarvinen H, Huovinen S, Hernriksson T, Herva E, *et al*., (1992). Resistance to ergthromycin in Group A Streptococci. N Englj Med; 326:292-7.

32. Stevens DL, (1996). Streptococcal Toxic Shock Syndrome: Spectrum of disease, pathogenesis and new concepts in treatment. Emerging Infectious diseases 1995; 1:69-78.

33. Stingemore, N Frances GR, Toohey M, McGreechie DB (1989). The emergence of erythromycin resistance in stryptococcus pyogenes in Fremantle, Western Australia. Med J Aust; 150: 626-31.
34. The UP24 (2000) Printed by National publishing Philadephia, PA. P 1826.
35. Threlk Ds ed (1998). Systemic anti infective, Macrolides. In fact and comparisons drug information. St. Louis, Mo: Fact and comparisons, Oct, 343-344.